Back to Search Start Over

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

Authors :
Loi, Sherene
Azambuja, Evandro
Pugliano, Lina
Sotiriou, Christos
Piccart-Gebhart, Martine
Loi, Sherene
Azambuja, Evandro
Pugliano, Lina
Sotiriou, Christos
Piccart-Gebhart, Martine
Source :
Current opinion in oncology, 23 (6
Publication Year :
2011

Abstract

There have been recent new developments in the treatment of breast cancer that over-expresses HER2 (ERRB2/HER2 positive) and the mechanistic understanding of trastuzumab response. We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype.<br />Journal Article<br />Research Support, Non-U.S. Gov't<br />Review<br />SCOPUS: re.j<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
Current opinion in oncology, 23 (6
Notes :
1 full-text file(s): application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn803496178
Document Type :
Electronic Resource